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Exploiting fourier transform infrared and Raman
microspectroscopies on cancer stem cells from
oral squamous cells carcinoma: new evidence of
acquired cisplatin chemoresistance
Valentina Notarstefano, †a Simona Sabbatini,†b Chiara Pro,a Alessia Belloni,a
Giulia Orilisi,c Corrado Rubini,d Hugh J. Byrne, e Lisa Vaccari f and
Elisabetta Giorgini *a
Oral Squamous Cells Carcinoma (OSCC) is characterised by the risk of recurrence and the onset of a
refractoriness response to chemotherapy drugs. These phenomena have been recently related to a sub-
population of Cancer Stem Cells (CSCs), which have either an innate or acquired drug resistance, trig-
gered by chemotherapy treatments. In this light, to precisely target chemotherapy regimens, it is essential
to improve knowledge on CSCs, with a particular focus on their molecular features. In this work, a sub-
population of CSCs, isolated by tumour sphere formation from primary OSCC cells, were treated with cis-
platin for 16, 24 and 48 hours and analysed by infrared absorption and Raman microspectroscopies. CSC
spectral data were compared with those obtained in previous work, for primary OSCC cells treated under
the same conditions. Routine viability/apoptosis cell-based assays evidenced in CSCs and primary OSCCs,
a similar degree of sensitivity to the drug at 24 hours, while a reversion of the conventional monotonic
time response exhibited by OSCCs was shown by CSCs at 48 hours. This peculiar time response was also
supported by the analysis of IR and Raman data, which pinpointed alterations in the lipid composition and
DNA conformation in CSCs. The results obtained suggest that CSCs, although sharing with OSCC cells a
similar sensitivity to cisplatin, display the onset of a mechanism of chemoresistance and enrichment of
resistant CSCs as a result of drug treatment, shedding new light on the severe issue of refractoriness of
some patients to chemotherapy conventionally used for OSCC.
Introduction
Oral Squamous Cell Carcinoma (OSCC) represents 90% of all
oral cavity tumours, and has a 5-year survival rate of ∼54%.1,2
Chemotherapeutic treatment is commonly prescribed, notably
with Cisplatin (cis-diamminedichloridoplatinum(II); cis-[Pt
(NH3)2(Cl)2]), which is successfully used against solid tumors,
including gastric cancer, Non-Small Cell Lung Cancer (NSCLC)
and OSCC.1 Cisplatin forms adducts with the N7 atom of the
purine nucleobase of DNA, resulting in inter- and intra-strand
DNA cross-linkages.3 The effects of this binding mechanism
are numerous and various, including the cell cycle arrest at the
G2/M checkpoint4 and the triggering of the apoptosis cascade,
as a consequence of DNA misfolding and degradation.5,6 A
serious issue related to OSCC is that many patients show a
recurrence after chemotherapy treatments,7 sometimes also
developing a refractoriness to drugs.8 Chemoresistance also
affects cisplatin-based therapeutic regimens, which, although
considered efficient against rapidly proliferating tumours, are
characterised by a risk of tumour relapse that ranges from
15–20% for ovarian cancer, to even 95% for NSCLC.3
Several studies have revealed that the mechanisms behind
this chemoresistance are in part related to the presence of
Cancer Stem Cell (CSCs) niches,9,10 cellular subpopulations
displaying clonogenic characteristics,11 able to stimulate
cancer growth and resistance to therapy.12,13 It has been†These authors equally contributed to the work.
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demonstrated that, in some cases, chemotherapy can result in
the development of more aggressive cell phenotypes14 (i.e.
cells with mutations which allow them to evade drug-induced
death15), or of a subpopulation of drug-resistant CSCs.16 The
relationship between CSCs and drug chemoresistance is a mul-
tifactorial process, relying, inter alia, on the alteration of the
mechanisms related to drug uptake/efflux and metabolism,17
fine regulation of cell cycle,3 efficacy of DNA repair,18–20 and
inhibition of apoptosis cascade triggering.21–23 CSCs from
OSCC, similar to other tumour types, can be enriched for
in vitro studies exploiting the tumour sphere formation assay,
which enables isolation of CSCs by culturing cancer cells in a
serum-free condition, supplemented with basic fibroblast and
epidermal growth factors.16,24 The aforementioned tumour
sphere-forming CSCs not only display stem cell properties,
including self-renewal, but also show strong tumorigenicity,
metastatic behavior, and drug resistance, confirming their role
in tumour growth and aggressiveness. In this context, since
CSCs fail to be eliminated by conventional chemotherapy and
tend to initiate new populations of cancer cells, possibly more
aggressive and drug-resistant, a complete knowledge of the
response of CSC populations to chemotherapy drugs used for
the treatment of OSCC, like cisplatin, may be crucial to shed
new light on the frequent cases of recurrence and hence to
improve the clinical outcome of treatment of this pathology.
Fourier Transform Infrared (FTIRM) and Raman (RMS)
Microspectroscopies are vibrational spectroscopic techniques,
successfully applied in life sciences to investigate the bio-
molecular structure and composition of cells and tissues.25–29
They can provide, on the same sample and at the same time,
an overview of the chemical composition and structure of the
cellular components. Indeed, the analysis of IR and Raman
bands in terms of position, intensity and width, enables the
molecular fingerprints of the most relevant biological mole-
cules (proteins, lipids, sugars and nucleic acids) within the
investigated samples to be determined. The information
acquired from IR and Raman spectra can be related to biologi-
cal processes, such that these vibrational techniques have sig-
nificant potential in diverse fields of biomedicine, such as
tissue diagnosis30 and drug toxicity evaluation.1,31
The combined use of FTIRM and RMS provides a complete
vibrational analysis of the sample, since the physical origin of
IR absorption and Raman scattering makes them mutually
complementary: FTIR spectroscopy is sensitive to polar (and
usually antisymmetric) vibrations, while Raman is sensitive to
polarisable (and usually symmetric) group vibrations.32
Furthermore, IR and Raman techniques differ in their spatial
resolution: conventional far-field FTIRM analysis guarantees a
spatial resolution of ∼10–20 μm, whereas, RMS can readily
achieve spatial resolutions of ∼1 μm. This makes FTIRM suit-
able for the analysis of individual cells or small cell assem-
blies, while RMS is preferred for subcellular analyses.33
In a previous study, the effects of cisplatin and 5-fluoroura-
cil on primary tumoral cells from OSCC by means of FTIRM
were assessed, highlighting a time-dependent drug-specific
cellular response, and providing additional information with
respect to routine assays (MTT and cytofluorimetry).1 Pursuing
this approach further, in the present study, Cancer Stem Cells
(CSCs) isolated from primary Oral Squamous Cells Carcinoma
(OSCC) samples were similarly in vitro treated with cisplatin,
and analysed by conventional cytotoxicity assays, as well as
both FTIRM and RMS, with the aim of highlighting possible
anomalies in CSC response, with respect to those previously
reported for primary OSCCs.1
Experimental
The study was approved by the Ethics Committee of Azienda
Ospedaliero Universitaria – Ospedali Riuniti, Ancona; it was
carried out in full accordance with ethical principles for experi-
ments involving humans, including The Code of Ethics of the
World Medical Association (Declaration of Helsinki). Patients,
who participated to this investigation, signed an informed
consent; moreover, all samples were assigned a code, in
accordance with privacy rights, and hence it was impossible to
relate them to patients. Patients were subjected to a standard
surgical procedure with diagnostic purposes. Cisplatin was
provided by Azienda Ospedaliero Universitaria – Ospedali
Riuniti Ancona (TEVA, Italia), and diluted with 0.9% NaCl to
the final concentrations.
Culture and isolation of cancer stem cells (CSCs) of oral
squamous cell carcinoma
Oral biopsy samples from lesions with diagnosis of poorly
differentiated Oral Squamous Cell Carcinoma, tumour grade 3
(assessed by histological analysis) were collected from 5
patients (3 males and 2 females; mean age 54.5 ± 8.6 years). All
samples were chopped into small fragments and cultured at
37 °C in a humidified atmosphere with 5% CO2, in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10%
Fetal Bovine Serum (FBS) and 1% penicillin–streptomycin
solution, to obtain primary tumour cell cultures. The growth
medium was changed every 48 hours and cell overgrowth was
controlled by selective trypsinisation (0.05% trypsin–0.02%
EDTA). Cells were routinely tested for mycoplasma contami-
nation. Once 90% of confluence was reached, primary OSCC
cells were detached with trypsin, counted using a hemocyt-
ometer, centrifuged (1200 rpm for 5 minutes), and pooled
together. For the sphere formation assay and CSCs enrich-
ment, OSCC cells were plated at a density of 1 × 105 cells per
well in 6-well plates in serum-free DMEM/F12 medium, sup-
plemented with human recombinant epidermal growth factor
(EGF; 10 ng ml−1) and basic fibroblast growth factor (bFGF; 20
ng ml−1). Fibroblasts spread after two weeks, while after one
month a different cell population appeared, characterised as
epithelial by immunocytochemical analysis with a cytokeratin
antibody. During this month of CSCs-enrichment, the culture
medium was changed every day, and fresh aliquots of EGF and
bFGF were supplemented every 2 days, until the formation of
tumour spheres, which were then used for subsequent
analyses.24
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The cisplatin concentration that reduced the viability of CSCs
by 50% (IC50) was determined by means of the colorimetric
MTT (3-[4,5-dimethylthiazol 2yl]diphenyltetrazolium bromide)
assay.34 The reduction by mitochondria of the yellow MTT
reagent to a purple formazan product is used to evaluate cellu-
lar viability. CSCs were seeded in 96-well plates (10 × 103 cells
per well) in DMEM/F12 with 2% Fetal Bovine Serum (FBS),
human recombinant epidermal growth factor (hrEGF; 20 ng
ml−1) and basic fibroblast growth factor (bFGF; 10 ng ml−1)
and incubated at 37 °C in a humidified atmosphere with 5%
CO2. After 24 hours, increasing concentrations of cisplatin (0,
2, 4, 6, 8 and 10 µg mL−1) were added and the cells were incu-
bated for a further 24 hours, at 37 °C and in a humidified
atmosphere with 5% CO2.
1 The experiments were repeated in
triplicate. Cells were then incubated with 5 mg mL−1 of MTT
for 3 hours at 37 °C; at the end of the treatment, the medium
containing MTT was removed and 100 μl of dimethyl-
sulphoxide (Sigma-Aldrich) were added to each well. The
number of viable cells was correlated to the intensity of the
purple formazan product, measured at 570 nm, by means of a
microplate reader (Synergy HT, Biotek, Winooski, VT, USA).
The ratios between the absorbance values measured of drug-
treated cells (named Cis) and those of untreated ones (named
Ctrl) were calculated and reported in viability curves as percen-
tages of viable cells against the inhibitory effect of the treat-
ments on the cellular mitochondrial activity [(Cisabs/Ctrlabs) ×
100]. The maximum of cell metabolic activity (100%) was
assumed for untreated control samples. The drug concen-
tration that reduced the viability of cells by 50% (IC50) was
determined by plotting triplicate data points over the concen-
tration range and used for cisplatin treatment in the
experiment.
Apoptosis assessment by Annexin V/PI staining
The apoptotic index of CSCs, after treatment with cisplatin,
was evaluated by using the Tali™ Apoptosis assay kit-Annexin
V Alexa Fluor® 488 and propidium iodide (Invitrogen, Milan,
Italy). CSCs were seeded into 6-well plates (2 × 105 cells per
well) in 3 ml DMEM/F-12 with 2% FBS, human recombinant
epidermal growth factor (hrEGF; 20 ng ml−1) and basic fibro-
blast growth factor (bFGF; 10 ng ml−1) and incubated over-
night at 37 °C in a humidified atmosphere with 5% CO2. Then,
cisplatin, at the IC50 calculated concentration (see cell viability
section), was added and the cells were incubated for 16, 24
and 48 hours at 37 °C in a humidified atmosphere with 5%
CO2. For each experimental group, additional cell aliquots
were cultured under the same conditions, without any chemo-
therapy treatment for 16, 24 and 48 hours (Ctrl). The experi-
ments were repeated in triplicate. For each time range, all cell
samples were washed twice with ice-cold PBS (pH 7.4), centri-
fuged, resuspended in 100 μL of Binding Buffer (BB) (106 cells
per ml) and incubated with 5 μL of TaliTM Annexin V Alexa
Fluor® 488 for 20 min at room temperature, in dark con-
ditions. Cells were centrifuged at 1000 rpm for 5 min, resus-
pended in 100 μL of BB and 1 μL of TaliTM Propidium Iodide
(PI) for an additional 5 min at room temperature in the dark
and analysed with flow cytometry (Tali® Image-based cyt-
ometer). After staining, the absence of, or low fluorescence was
indicative of live cells; green fluorescence (positive to Annexin
V and negative to PI) was indicative of early apoptotic cells;
red/green (positive to both dyes) fluorescence was indicative of
late apoptotic cells.1 The percentages of live (L), early apoptotic
(EA) and late apoptotic/dead (LA/D) cells were determined
based on the respective fluorescence histograms compared
with control ones.35
CSCs in vitro treatment for FTIRM and RMS measurements
CSCs were seeded into 6-well plates (1 × 105 cells per well),
incubated overnight at 37 °C in a humidified atmosphere with
5% CO2 and then treated with cisplatin (6.3 µg mL
−1) for 16,
24 and 48 hours (Cis-16, Cis-24 and Cis-48 experimental
groups).1 Other aliquots of CSCs, used as control groups, were
normally cultured without any drug for the same time points
(Ctrl-16, Ctrl-24, and Ctrl-48). At each selected time point, cells
were harvested by trypsinisation and centrifuged at 1200 rpm
for 5 min; pellets were washed twice with DMEM.
FTIRM measurements and data analysis
FTIRM measurements were performed in duplicate at the
Chemical and Life Sciences branch of the Infrared Beamline
SISSI (Synchrotron Infrared Source for Spectroscopic and
Imaging), Elettra Sincrotrone Trieste (Trieste, Italy) (Proposal
N. 20150225). A Hyperion 3000 Vis-IR microscope coupled
with a Vertex 70 V interferometer and equipped with a HgCdTe
(MCT_A) detector and (Bruker Optics, Ettlingen, Germany) was
used. CSCs were resuspended with 15 μL of DMEM and de-
posited, without any further treatment, into a specific in-
house built biocompatible IR transparent microfluidic device
for in vitro FTIRM analysis. The device, available at SISSI beam-
line, consists of two CaF2 optical windows (0.5 mm thick, 13
and 10 mm diameter, respectively), spaced apart 7.5 μm.36 For
each sample, ∼120 microareas (30 × 30 μm2) containing
densely packed cell monolayers were selected by visible
microscopy. On these areas, IR spectra were collected in trans-
mission mode in the MIR region (4000–800 cm−1), averaging
512 scans (spectral resolution 4 cm−1, zero-filling factor 2,
scanner velocity 40 kHz). A background spectrum was acquired
on a CaF2 clean window before each sample acquisition, while
a buffer medium spectrum was collected each 10 cells spectra:
in both cases, the same parameters for cell acquisition were
used. All the collected raw spectra were corrected for the con-
tribution of atmospheric carbon dioxide and water vapor with
the Atmospheric Compensation routine of OPUS 7.5 software
(Bruker Optics GmbH). Hence, the spectral contributions of
the medium were subtracted by running an in-house opti-
mised Matlab routine.1,36 Hence, IR spectra showing a peak
height at 1660 cm−1 (Amide I band of proteins) lower than
0.07 a.u. were discarded. The remaining pre-processed spectra
were vector-normalised and converted in Second Derivative
mode (Savitzky–Golay filter, 9 points of smoothing) (OPUS 7.5
Paper Analyst



















































software). These spectra were then subjected to multivariate
analysis, with no further pre-processing. Principal
Components Analysis (PCA) was first employed as an unsuper-
vised multivariate approach to analyze spectral data of CSCs.37
The pairwise PCA of Ctrl-16/Cis-16, Ctrl-24/Cis-24, Ctrl-48/Cis-
48, and Cis-16/Cis-48 spectra was performed, on the Regions
Of Interest (ROI) 3050–2800 cm−1 and 1350–900 cm−1. The
1800–1350 cm−1 spectral range was not taken into account,
since the water subtraction procedure inevitably affects the
reliability of the spectral information. PCA was coupled with
linear discriminant analysis (LDA): PCA was used to reduce
redundant information from the spectral data set, by describ-
ing each spectrum with a subset of PCs, together explaining
95% of cumulative variance; then, the reduced spectral
datasets were used as input variables for LDA (OriginPro
2018b software, OriginLab Corporation, Northampton,
Massachusetts).30,38 To quantify the identified alterations due
to cisplatin treatment, for each experimental group, the
average absorbance spectrum, together its standard deviation
spectra (average absorbance spectra ± standard deviation
spectra) were calculated (Averaging routine, OPUS 7.5 soft-
ware). These spectra were curve fitted in the 3050–2800 and
1350–900 cm−1 spectral regions. The number and position
(expressed as wavenumbers) of the underlying bands were
identified by second derivative minima analysis and fixed
during fitting procedure with Gaussian functions (GRAMS/AI
9.1, Galactic Industries, Inc., Salem, New Hampshire). The
integrated areas of the underlying bands were used to calculate
the following band area ratios: 2925/2960, 1240/TOT, 1220/
TOT, 1170/TOT, 1085/TOT, 1054/TOT, 1020/TOT, 994/TOT, 970/
TOT. TOT was calculated by the sum of the integrated areas of
all the underlying bands in the 1350–900 cm−1 spectral range.
RMS measurements and data analysis
RMS measurements were performed in duplicate at the FOCAS
Research Institute, Technological University Dublin (Ireland).
A Horiba Jobin–Yvon LabRAMHR800 spectrometer, equipped
with a 532 nm diode laser (∼50 mW laser power at the sample)
was used as source. Just after cisplatin treatments, CSCs were
fixed in a 4% paraformaldehyde (PFA) solution for 10 minutes,
washed twice in physiological solution, and stored at 4 °C.
This procedure has been validated to retain the biochemical
profile of the cells as close as possible to that of live cells,39
preserving hydration, and protecting them from biological
damage during shipping.26,28 All measurements were acquired
by using a ×100 objective (Olympus, N.A. 1). The spectrometer
was calibrated to the 520.7 cm−1 line of silicon prior to spectral
acquisition. A 600 lines per mm grating was chosen. A 100 μm
confocal pinhole was used for all measurements. The spectra
were dispersed onto a 16-bit dynamic range Peltier cooled CCD
detector. The spectral range from 600 to 1800 cm−1 was
chosen and spectra were acquired for 3 × 10 seconds at each
spot. For each sample, ∼40 point spectra were acquired from
cells seeded on the glass slide; spectra displayed homogeneous
profiles. No contribution of glass to the spectra was observed.
Raman spectra were smoothed using 9 smoothing points,
baseline-corrected with the polynomial method (2 iterations)
(OPUS 7.5 software), and then submitted to multivariate ana-
lysis. Principal Components Analysis (PCA) was first employed
as an unsupervised multivariate approach to analyze spectral
data of CSCs.37 The pairwise PCA of Ctrl-16/Cis-16, Ctrl-24/Cis-
24, Ctrl-48/Cis-48, and Cis-16/Cis-48 spectra was performed.
PCA was coupled with linear discriminant analysis (LDA): PCA
was used to reduce redundant information from the spectral
data set, by describing each spectrum with a subset of PCs,
together explaining 95% of cumulative variance; then, the
reduced spectral datasets were used as input variables for
LDA (OriginPro 2018b software, OriginLab Corporation,
Northampton, Massachusetts).30,38 To quantify the identified
alterations due to cisplatin treatment, the height of some
selected peaks of interest was calculated (integration mode K,
OPUS 7.5 software).
Statistical analysis
Normally distributed data deriving from FTIRM and RMS
spectra were presented as mean ± S.D. Significant differences
between experimental groups were determined by means of a
factorial analysis of variance (one-way ANOVA), followed by
Tukey’s multiple comparisons test, by the statistical software
Prism6 (Graphpad Software, Inc. USA). One-way ANOVA com-
pares the means of Ctrl-16, Ctrl-24, Ctrl-48, Cis-16, Cis-24 and
Cis-48 groups in order to make inferences about the popu-
lation means. Statistical significance was set at p < 0.05.
Different letters over box charts indicate statistically signifi-
cant differences among the above defined experimental
groups.
Results
In this study, we present the results of in vitro FTIRM and RMS
analysis of Cancer Stem Cells (CSCs) from Oral Squamous
Cells Carcinoma (OSCC) treated with cisplatin at the dose of
6.3 µg mL−1 for 16, 24 and 48 hours.1 The cellular viability and
the apoptotic response of CSCs to this chemotherapy treat-
ment were evaluated by using MTT assay and image-based
cytometry with AnnexinV/PI staining, respectively. Fig. 1 shows
the primary cell culture before (Fig. 1A) and after (Fig. 1B)
Fig. 1 CSCs-enrichment (‘sphere formation’) of the population of
primary oral squamous cells carcinoma, grade 3 (OSCC). (A) Primary
culture of OSCC; (B) CSCs-enriched primary culture. (10 ×
magnification).
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CSCs-enrichment, a process which is known as ‘sphere
formation’.
Dose–response curves and IC50 values
The MTT assay was performed to assess the sensitivity of CSCs
towards cisplatin. Viability curves highlighted an in vitro dose-
dependent anti-proliferative action for the chemotherapeutic
drug (Fig. 2).
The IC50 value was determined to be 6.3 μg mL−1, which is
similar to that of 7 μg mL−1 observed for primary OSCCs,1 also
depicted in Fig. 2, indicating that the CSCs and primary OSCC
cultures are at least, if not more sensitive, to the chemothera-
peutic agent.
Apoptosis rates
The percentages of viable, early apoptotic and late apopto-
tic/dead CSCs were assessed after 16, 24, and 48 hours of
treatment with cisplatin (6.3 µg mL−1), by means of image-
based cytometry. The results, reported in Fig. 3, confirm
that cisplatin induced cell death through apoptosis, and a
similar loss of viability was observed for the CSC and
primary OSCC cultures was observed after 16 hours of treat-
ment (Fig. 3A).
However, whereas the viability of the OSCC cultures contin-
ued to monotonically decrease with increasing treatment time,
the same percentage of viable cells (51%) was observed at 16
and 24 hours for the CSC cultures, and the value was seen to
increase at 48 hours (63%). The rate of early apoptotic CSCs
initially showed a decreasing trend according to treatment
time, before stabilising or increasing slightly at 48 hours (20%,
9% and 11%, at 16, 24 and 48 hours, respectively; Fig. 3B),
while the percentages of late apoptotic/dead cells were seen to
initially increase, as expected, from 29% at 16 hours to 41% at
24 hours, but then decrease again to the lowest value of 26%
at 48 hours (Fig. 3C). In this respect, the behavior exhibited by
the CSCs at 16-24 hours is consistent with that of the primary
OSCCs1 but at the later time point, the reduced percentage of
late apoptotic/dead cells is suggestive of a reduced drug
sensitivity.
FTIRM analysis
Fig. 4 displays the average IR spectra of each experimental
group, both in absorbance (Fig. 4A) and in second derivative
(Fig. 4B) mode, in the 3050–2800 cm−1 and the 1770–900 cm−1
spectral ranges. To test the homogeneity and stability of
control groups, a PCA was performed using all spectra of Ctrl-
16, Ctrl-24 and Ctrl-48 cell populations and no segregation was
found according to either PC1 or PC2 (data not shown). Then,
the pairwise PCA analysis between control and treated groups
at each time point was performed, in the ROI 3050–2800 cm−1
and 1350–900 cm−1. Fig. 5 displays the pairwise PCA scatter
plots of CSC 2nd derivative IR spectra for Ctrl-16/Cis-16, Ctrl-
24/Cis-24, Ctrl-48/Cis-48, and Cis-16/Cis-48 groups, together
with their relative loadings. Little or no segregation according
Fig. 2 Dose–response curve for CSCs treated with 0, 2, 4, 6, 8, and
10 µg mL−1 of cisplatin for 24 hours (black squares). For comparisons,
dose–response data for primary OSCCs from the previous work1 are
also depicted (red squares). Data are reported as mean ± SD of triplicate
measurements.
Fig. 3 Percentages of viable, early apoptotic, and late apoptotic/dead
CSCs treated for 16, 24 and 48 hours with cisplatin (6.3 µg mL−1) (Cis)
and no treatment (Ctrl). For comparisons, percentages of viable, early
apoptotic, and late apoptotic/dead primary OSCCs from the previous
work1 are also depicted. Data are reported as mean ± SD of triplicate
measurements.
Fig. 4 Average of Ctrl-16, Ctrl-24, Ctrl-48, Cis-16, Cis-24 and Cis-48
absorbance spectra (A), and their second derivative modes (B), in the
3010–900 cm−1 spectral region. For a better viewing, spectra are off
set along y-axis.
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PC1 was detectable in either Ctrl-16/Cis-16 (16 hours of treat-
ment, Fig. 5A) or Ctrl-48/Cis-48 (48 hours of treatment,
Fig. 5C) scatter plots, whereas an almost complete segregation
was observed at 24 hours of treatment (Ctrl-24/Cis-24 scatter
plot, Fig. 5B). For a more comprehensive overview on the spec-
tral changes characterizing the treated CSCs at 48 hours, a
comparison between Cis-16 and Cis-48 groups was performed,
and no segregation was found (Fig. 5D). In the right column of
Fig. 5, the PC1 loading spectra corresponding to each pairwise
comparison are reported.
The analysis of PC1 loadings (Fig. 5E–H) confirmed the
trend suggested by the scatter plots, showing strong spectral
modifications only for the Ctrl-24/Cis-24 comparison. The
most discriminant spectral features highlighted by the loading
spectra were the following: 2960 cm−1, 2925 cm−1 and
2850 cm−1 (assigned to lipid alkyl chains);30 1240 cm−1 and
1220 cm−1 (assigned to phospholipids and nucleic acids);40–42
1120 cm−1 and 994 cm−1 (assigned to RNA);1,43,44 1085 cm−1
(assigned to nucleic acids);43 1170 cm−1, 1054 cm−1 and
1025 cm−1 (assigned to carbohydrates),1,5,30,44 and 970 cm−1
(assigned to DNA).26,43,44
The coupling of PCA with LDA enabled a more quantitative
analysis of the degree of differentiation of the control and
treated datasets at the different timepoints. The LDA models
were tested by a leave-one-out cross validation procedure, by
which the number of PCs was chosen to account for 95% of
cumulative variance.45 For Ctrl-16/Cis-16 comparison, 12 PCs
were used as input for LDA, resulting in a 2.38% error; for
comparison of Ctrl-24/Cis-24, 8 PCs were used, resulting in a
0.67% error rate; for Ctrl-48/Cis-48, 9 PCs were used resulting
in a 12.52% error rate, while for comparison of Cis-16/Cis-48,
15 PCs were used resulting in a 3.07% error rate.
The lowest error rate of <1% for the comparison of Ctrl-24/
Cis-24 is an indication of the best degree of differentiation of
the two datasets, and therefore strongest effect of the drug,
after 24 hours treatment, while the higher error rates for the
other comparisons indicate a greater degree of similarity,
notably for the Ctrl-48/Cis-48 comparison, indicating a greater
degree of similarity of the CSCs treated for 48 hours and the
control samples.
Data obtained from the absorbance spectra were employed
to interpret the information from loadings of second deriva-
tive spectra. For this purpose, for each experimental group,
the average IR absorbance spectrum was calculated, together
with its standard deviation spectra (average absorbance
spectra ± standard deviation spectra). By curve fitting pro-
cedure, several underlying bands with biological meaning
were selected in the spectral ranges 3050–2800 and
1350–900 cm−1. Their position (in terms of wavenumbers) is
reported in Table 1, together with the corresponding
vibrational modes, putative biochemical assignments and
appropriate references.
Hence, the following band area ratios were calculated and
analysed as follows (Fig. 6): (i) no statistically significant
change was observed in all the analysed band area ratios
Fig. 5 Multivariate analysis of FTIRM data. Pairwise PCA scatter plots
calculated for: (A) Ctrl-16/Cis-16, (B) Ctrl-24/Cis-24, (C) Ctrl-48/Cis-48,
(D) Cis-16/Cis-48 spectra. PC1 loading profiles of (E) Ctrl-16/Cis-16, (F)
Ctrl-24/Cis-24, (G) Ctrl-48/Cis-48 spectra, and (H) Cis-16/Cis-48 pairs.
For clarity purposes, PCA loadings are plot with different Y scales for the
two ROI (3050–2800 cm−1 and 1350–900 cm−1).
Table 1 Centre position (wavenumbers), vibrational mode and bio-
chemical assignment of the underlying bands as identified by curve
fitting analysis of average absorbance spectra of the experimental
groups in the spectral ranges 3050–2800 and 1350–900 cm−1
Wavenumbers
(cm−1) Vibrational mode and biochemical assignment
∼2960 Asymmetric stretching vibration of CH3 groups of
branched aliphatic chains of lipids30
∼2925, ∼2850 Asymmetric and symmetric stretching vibrations of
CH2 groups of linear aliphatic chains of lipids
30
∼1240 Asymmetric stretching vibrations of phosphate
moieties of A-form DNA40–42
∼1220 Asymmetric stretching vibrations of phosphate
moieties of B-form DNA40–42
∼1170 Stretching vibration of C–C, C–O–C and C-OH groups
in carbohydrates1
∼1120 Stretching vibration of the skeletal structure around
the C2′−OH group of RNA and NTPs1,43
∼1085 Symmetric stretching vibrations of phosphate
moieties in nucleic acids43
∼1054 Stretching vibration of C–OH groups in
carbohydrates30,44
∼1025 Stretching vibration of CH2–OH moieties in
carbohydrates1,5
∼994 C–C, C–O ring breathing of RNA ribose1,43,44
∼970 Backbone vibrations of nucleic acids, mainly double-
strand DNA26,43,44
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among all control groups (Ctrl-16, Ctrl-24 and Ctrl-48) (p >
0.05); (ii) the band area ratio 2925/2960 (representing the
length/branching of lipid aliphatic chains) significantly
increased in Cis-24 and Cis-48, with respect to all the control
groups and Cis-16 (p < 0.05) (Fig. 6A); (iii) the band area ratio
1240/TOT (assigned to vibrations of phosphate groups mainly
assigned to A-form DNA) significantly increased in Cis-24 and
Cis-48, with respect to all the control groups and Cis-16 (p <
0.05) (Fig. 6B); (iv) the band area ratio 1220/TOT (assigned to
vibrations of phosphate groups of B-form DNA) significantly
decreased in all cisplatin-treated groups, with respect to
control ones (p < 0.05) (Fig. 6C); (v) the band area ratio 1085/
TOT (nucleic acids) significantly decreased in Cis-24 (p < 0.05),
while no significant change was observed at 16 and 48 hours
of treatment (p > 0.05) (Fig. 6F); (vi) the band area ratio 970/
TOT (double-stranded DNA backbone) significantly decreased
only in Cis-16 and Cis-24 (p < 0.05) (Fig. 6J); (vii) the band area
ratios 1120/TOT and 994/TOT (both related to RNA) did not
display the same trend, with no significant alteration in 1120/
TOT among all the experimental groups (p > 0.05) (Fig. 6E),
and a significant decrease of the band area ratio 994/TOT in
all cisplatin-treated cells (p < 0.05) (Fig. 6I); (viii) the band area
ratio 1170/TOT (representing the C–C, C–O–C and C-OH
groups in carbohydrates) showed a significant decrease in Cis-
16 and especially in Cis-24 cells (p < 0.05), while no difference
was detected at 48 hours of treatment with respect to control
ones (p > 0.05) (Fig. 6D); (ix) the band area ratio 1054/TOT
(representing the C–OH group in carbohydrates) showed a sig-
nificant decrease only in Cis-24 experimental group (p < 0.05)
(Fig. 6G), and (x) the band area ratio 1025/TOT (representing
the CH2–OH moieties in carbohydrates) showed the same
trend as the 1170/TOT one, with a general significant decrease
in all cisplatin-treated cells (p < 0.05) and, in particular, with
comparable values at 16 and 48 hours of treatment (p > 0.05)
(Fig. 6H).
RMS analysis
Fig. 7 displays average Raman spectra of each experimental
group, in the 1800–600 cm−1 spectral range. To test the hom-
ogeneity and stability of control groups, a PCA was performed
using all RMS spectra of Ctrl-16, Ctrl-24 and Ctrl-48 cell popu-
lations and no segregation was found along PC1 and PC2 (data
not shown). Then, the pairwise PCA analysis between control
and treated groups at each time point was performed. Fig. 8
displays the pairwise PCA scatter plots of CSCs Raman spectra
from Ctrl-16/Cis-16, Ctrl-24/Cis-24 and Ctrl-48/Cis-48 groups,
together with their relative loadings. No segregation according
PC1 was detectable in Ctrl-16/Cis-16 scatter plot (Fig. 8A); the
segregation of spectra was almost complete at 24 hours of
treatment (Ctrl-24/Cis-24 scatter plot, Fig. 8B); no segregation
Fig. 6 Histograms showing the numerical variation of the following band area ratios calculated for Ctrl-16, Ctrl-24, Ctrl-48, Cis-16, Cis-24 and Cis-
48: (A) 2925/2960, (B) 1240/TOT, (C) 1220/TOT, (D) 1170/TOT, (E) 1120/TOT, (F) 1085/TOT, (G) 1054/TOT, (H) 1025/TOT, (I) 994/TOT, and (J) 970/TOT.
Data are represented as mean ± SD. Different letters over histograms indicate statistically significant difference among groups (one-way ANOVA and
Tukey’s multiple comparison test). Statistical significance was set at p < 0.05.
Fig. 7 Average RMS spectra of Ctrl-16, Ctrl-24, Ctrl-48, Cis-16, Cis-24
and Cis-48 samples interpolated in the 1800–600 cm−1. For a better
viewing, spectra are shifted along y-axis.
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was evident at 48 hours of treatment (Ctrl-48/Cis-48 scatter
plot, Fig. 8C). For a more comprehensive overview on the spec-
tral changes characterizing the treated CSCs at 48 hours, a
comparison between Cis-16 and Cis-48 groups was performed,
and no segregation was found (Fig. 8D). In the right column of
Fig. 8, the PC1 loading spectra corresponding to each pairwise
comparison are presented. The analysis of PC1 loadings
(Fig. 8E–H) confirmed the trend suggested by the scatter plot,
showing profound spectral modifications only in the case of
Ctrl-24/Cis-24 comparison. The most discriminant spectral fea-
tures highlighted by the loading spectra are: 728 cm−1,
785 cm−1, 833 cm−1, 1095 cm−1 and 1340 cm−1 (assigned to
DNA);45–49 1005 cm−1 (assigned to proteins);26,50 1245 cm−1
(assigned to proteins and/or DNA);49,51 1307 cm−1 and
1445 cm−1 (assigned to lipids),49,51 and 1657 cm−1 (assigned to
proteins).26,52
The coupling of PCA with LDA enabled a more quantitative
analysis of the degree of differentiation of the control and
treated datasets at the different timepoints. The LDA models
were tested by a leave-one-out cross validation procedure, by
which the number of PCs was chosen to account for 95% of
cumulative variance.45 For Ctrl-16/Cis-16 comparison, 5 PCs
were used as input for LDA, resulting in a 35.15% error; for
comparison of Ctrl-24/Cis-24, 4 PCs were used, resulting in a
8.78% error rate; for Ctrl-48/Cis-48, 5 PCs were used resulting
in a 18.37% error rate, while for comparison of Cis-16/Cis-48, 7
PCs were used resulting in a 15.76% error rate. As was the case
for the FTIRM analysis, the lowest error rate, and therefore the
best degree of differentiation is observed for the comparison
of the Ctrl-24/Cis-24 datasets, and the results are consistent
with a lower degree of drug sensitivity after 48 hours of
treatment.
The positions of the peaks selected by the analysis of the
PCA loading spectra, together with the corresponding
vibrational modes, putative biochemical assignments and
appropriate references, are reported in Table 2.
For a comprehensive overview of the biochemical altera-
tions induced by cisplatin treatment at each time point, the
height of the peaks identified in the PCA loading spectra was
calculated from Raman spectra of the six experimental groups
and statistically analysed as follows: (i) no statistically signifi-
cant change was observed in all the analyzed band area ratios
among all control groups (p > 0.05) (Ctrl-16, Ctrl-24 and Ctrl-
48); (ii) no alteration in protein amount and/or structure was
observed in all cisplatin-treated groups, as evidenced by the
height of the peaks centered at 1657 cm−1 (representing the
overall protein content of cells) (Fig. 9A), 1005 cm−1 (represent-
ing the phenylalanine amino acid, Fig. 9F) and 1245 cm−1
(representing proteins, also related to α-helix structures,26,53
data not shown) (p > 0.05); (iii) the height of the band centered
at 1445 cm−1 (representing CH2 groups in lipids) was signifi-
cantly higher in Cis-24 (p < 0.05) (Fig. 9B); (iv) the height of
the band centered at 1307 cm−1 (representing CH3 and CH2
groups in lipids) resulted significantly higher in all cisplatin-
treated groups (p < 0.05) (Fig. 9D); (v) the height of the peak at
1340 cm−1 (representing adenine and guanine of DNA) did not
show significant alteration related to cisplatin treatment (p >
0.05) (Fig. 9C); (vi) the height of the bands centered at
1095 cm−1 and 785 cm−1 (both representing the DNA back-
bone) resulted significantly lower especially in the Cis-16 and
Cis-24 (p < 0.05) (Fig. 9E and H), and (vii) the height of the
peaks centered at 833 cm−1 and at 728 cm−1 (both represent-
ing DNA in its natural B-form) resulted significantly lower in
cisplatin-treated cells, with the lowest value in Cis-24 (p < 0.05)
(Fig. 9G and I).
Fig. 8 Multivariate analysis of RMS data. Pairwise PCA scatter plots cal-
culated for: (A) Ctrl-16/Cis-16, (B) Ctrl-24/Cis-24, (C) Ctrl-48/Cis-48, (D)
Cis-16/Cis-48 spectra. PC1 loading profiles of (E) Ctrl-16/Cis-16, (F)
Ctrl-24/Cis-24, (G) Ctrl-48/Cis-48 spectra, and (H) Cis-16/Cis-48
comparisons.
Table 2 Centre position (Raman shifts), vibrational mode and bio-
chemical assignment of the bands identified in the 600–1800 cm−1
spectral region of Raman average spectra of the experimental groups
Raman shifts
(cm−1) Vibrational mode and biochemical assignment
∼1657 Stretching vibration of amidic CvO groups26,52
∼1445 CH2 bending modes of lipid chains49
∼1340 Ring breathing modes of adenine and guanine of
DNA48,49
∼1307 CH3/CH2 twisting or bending mode of lipid49,51
∼1245 Amide III (C–N stretching, N–H bending) of proteins,
and/or PO2
− asymmetric stretching49,51
∼1095 Symmetric PO2− stretching vibration of DNA
backbone46,49
∼1005 Symmetric stretching breathing vibration of
phenylalanine26,50
∼833 O–P–O asymmetric stretching of DNA B-form46,48
∼785 O–P–O stretching of DNA backbone45,47
∼728 O–P–O stretching of DNA B-form46
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A crucial issue related to Oral Squamous Cells Carcinoma
(OSCC) is the recurrence of this pathology after chemo-
therapy treatments and the onset of a refractoriness
response to drugs,7,8 which contributes to the limited, 5-year
survival rate of ∼54% of patients. To address this, the need
for further studies which may shed new light on OSCC
response to chemotherapy treatments is clear. The strong
relationship between chemoresistance and the existence of a
niche of Cancer Stem Cells (CSCs) has been widely con-
firmed by several studies.12,13,54 Moreover, it is reported
that chemotherapeutic agents may contribute to triggering
the development of a subpopulation of drug-resistant
CSCs.16,55,56 All these aspects have contributed to the emer-
ging interest in studying CSCs of several tumour typologies,
including OSCC, to increase the knowledge of their mole-
cular features and to precisely target them in chemotherapy
regimens.57,58
In a previous work, the effects of cisplatin on primary
tumoral cells from OSCC were assessed by means of FTIRM,
highlighting a time-dependent, drug-specific cellular response,
and providing additional information with respect to routine
assays.1 Given the already established chemoresistance,
affecting cisplatin therapeutic regimens,17 and to contribute to
understanding the severe issue of refractoriness of some
patients to conventionally used chemotherapy,3 in the present
study, CSCs, isolated by tumour sphere formation from
primary OSCC cells and treated with cisplatin, were analysed
exploiting both FTIRM and RMS, with the aim of elucidating
possible anomalies in CSCs response, with respect to primary
OSCC cells.
Both routine viability/apoptosis cell-based assays and
vibrational analyses evidenced a peculiar time response of CSCs
to cisplatin treatment. In particular, the image-based cytometry
evidenced the same percentage of viable cells (51%) at 16 and
24 hours, which then increased at 48 hours (63%); in contrast, a
decreasing trend was exhibited by the apoptosis rate from 16 to
48 hours. A particular behaviour was evidenced in death percen-
tages, with a 29% of dead cells at 16 hours, 41% at 24 hours,
and 26% at 48 hours. In general, all these results confirm the
induction of cell death through apoptosis by cisplatin,1 while
also suggesting the onset of a mechanism of enrichment of
drug-resistant CSCs. The peak of dead cells percentage at
24 hours may be explained, considering it as a result of the
highest value of early apoptotic cells at the previous time point
(16 hours); conversely, the halving of apoptotic cells at 24 hours
and 48 hours determined, at these time points, the increase of
viable cells and the decrease of dead ones, these latter resulting
at 48 hours comparable to 16 hours. These results reflect a
reversion of the conventional time response exhibited by
primary OSCC cells, which, treated under the same conditions,
exhibited a monotonic decrease of their viability, consistently
coupled with a monotonic increase of cell death.1 Comparing
the cytotoxicity of the drug to the CSC cultures to that of the
primary OSCC cultures using the MTT assay, previously pub-
lished,1 it is clear that the CSCs have a similar degree of sensi-
tivity to the drug, at 24 hours. The flow cytometric study demon-
strates, however, that the cytotoxic profiles of CSCs diverge after
24 hours, suggesting the evolution of a more resistant CSC
culture at 48 hours. The peculiar time response was also sup-
ported by spectroscopic evidence and may be explained by con-
sidering the enrichment, along the experiment, of a subpopu-
lation of cells resistant to cisplatin, as a direct consequence of
the cisplatin treatment itself.55,59
PCA pairwise comparisons of both infrared and Raman
spectra evidenced a clear segregation of control and treated
CSCs’ spectra only at 24 hours of treatment, while no signifi-
cant difference was highlighted, either at 16 hours or at
48 hours. A further comparison was performed between Cis-16
and Cis-48 experimental groups, which showed no segregation.
CSCs are known to be highly heterogeneous,54 and hence it is
plausible that the onset of apoptosis in the first time step,
determining the death of drug sensitive cells, caused the
enrichment of a drug-resistant subpopulation. Furthermore,
the acquisition of chemoresistance, even in tumours that are
firstly sensitive to the chemotherapy, is a well-known and
partly characterised phenomenon, which relies on the modu-
lation of the expression of different genes and signaling
pathways.60,61 Another aspect that should be taken into
account is that CSCs formed tumor spheres in culture: these
three-dimensional structures, which partly mimic the in vivo
microenvironments of CSCs, can provide a protection against
anticancer drugs. In this light, it is possible to hypothesise
that the onset of apoptosis in the first time-step reflected the
activity of cisplatin against external CSCs, determining their
death, but also enriching the subpopulation of CSCs internal
to the tumor spheres, which continued to proliferate.62
Fig. 9 Histograms showing the numerical variation of the following
peak heights calculated forCtrl-16, Ctrl-24, Ctrl-48, Cis-16, Cis-24, and
Cis-48: 1657 (A), 1445 (B), 1340 (C), 1307 (D), 1095 (E), 1005 (F), 833 (G),
785 (H), 728 (I). Data are represented as mean ± SD. Different letters
over histograms indicate statistically significant difference among
groups (one-way ANOVA and Tukey’s multiple comparison test).
Statistical significance was set at p < 0.05.
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For CSCs treated with cisplatin, FTIRM and RMS data
suggest a mode of action consistent with the one shown in
primary OSCC cells.1 It is known that the apoptosis-related
accumulation of cytoplasmic lipid droplets is related with an
increase of total lipid content and of the methylene to methyl
groups.1,63,64 In this light, the onset of an apoptotic process
may be suggested in cisplatin-treated CSCs by the alteration
affecting the lipid component, with an increase of the length
and branching of lipid aliphatic chains (2925/2960 IR band
area ratio; 1445 cm−1 and 1307 cm−1 Raman peaks). The same
conclusion was drawn in the previous study of primary OSCC
cells, wherein the increase of the total amount of lipids signifi-
cantly affected only cells treated for 48 hours.1
Cisplatin-treated CSCs also showed changes in the DNA
conformation, with an increase of the A-DNA form (1240/TOT
IR band area ratio) and the decrease of the B-DNA form (1220/
TOT IR band area ratio; 833 cm−1 and at 728 cm−1 Raman
peaks). The B-conformation of DNA is typical of fully hydrated
conditions; hence, a reliable spectral marker of ongoing de-
hydration and of the transition of DNA to an A-conformation,
is the shift of the 1220 cm−1 peak towards higher wavenum-
bers.42 Since in our FTIRM experiment, cells were kept in
hydrated conditions, the alterations in relative intensities of
1240 cm−1 and 1220 cm−1 peaks were not attributable to
changes in hydration. It is reported that the B- to A-DNA tran-
sition also occurs during drug treatments, especially with
intercalating compounds, which interrupt base pairing, deter-
mining the shift of DNA to more disordered A forms.5,41,46,65
These results also appear in accordance with those related to
the infrared band area ratios 1085/TOT (nucleic acids) and
970/TOT (double-stranded DNA backbone), and of the Raman
peaks at 1095 and 785 cm−1 (DNA backbone), whose decrease
suggests an extensive fragmentation and rearrangement of
DNA, related to apoptosis mechanisms, induced by the cispla-
tin treatment.1,5 A reduction of the transcriptional activity was
also found in cisplatin-treated CSCs, probably attributable to
the previously highlighted DNA misfolding and fragmentation
(994/TOT IR band area ratio). Although not exhibiting the
same trend, as previously discussed, these results are in
accordance with those reported in the previous study of
primary OSCC cells: primary OSCC cells treated for 48 hours
showed an increase in the ∼1240 cm−1 subpeak and a decrease
of the ∼1220 cm−1 subpeak, together with a decrease of the
∼1085 cm−1 subpeak.
Notably, most of the modifications described in the spectral
profile were not observed in CSCs treated for 48 hours. The
values of IR band area ratios and Raman peak intensities at
48 hours were similar to those at 16 hours. This aspect,
together with the lack of segregation displayed by PCA and the
higher error rates of cross-validation of LDA results for Ctrl-16/
Cis-16, Ctrl-48/Cis-48, and Cis-16/Cis-48 comparisons, con-
firms the hypothesis based on the results of MTT and the flow
cytometry assay: CSCs, initially sensitive to cisplatin, with a
peak of response at 24 hours of treatment, acquire a chemore-
sistance and revert to a spectral profile similar to the one
measured at 16 hours, at which the heterogeneous population
of CSCs was not significantly affected by the chemotherapeutic
agent.
In conclusion, in this work, for the first time, the spectral
characterization of the macromolecular composition of Cancer
Stem Cells (CSCs) from OSCC, was performed, by FTIRM and
RMS, together with the assessment of the cisplatin-induced
cytotoxicity. The spectral results here obtained were compared
with those related to OSCC primary cells: a significantly
different cellular response to cisplatin was detected respect to
OSCCs, with CSCs showing the onset of a chemoresistance
mechanism with the enrichment of a population of cisplatin-
resistant CSCs. This evidence possibly sheds new light on the
severe issue of refractoriness of some patients to chemo-
therapy conventionally used for oral squamous cells
carcinoma.
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